Inventor Search

=> d ibib abs hitstr l10 1-3

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:394037 HCAPLUS
DOCUMENT NUMBER: 129:36430
TITLE: **Screening** assays for compounds
INVENTOR(S): **Hirth, Klaus Peter**; App, Harald; Tsai, Jianming
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5763198	A	19980609	US 1994-279321	19940722
PRIORITY APPLN. INFO.:			US 1994-279321	19940722

AB The invention is directed to rapid and quant. assay systems for **screening** test compds. for their ability to modulate tyrosine kinase or phosphatase activities involved in signal transduction by detg. the tyrosine phosphorylation state of a protein substrate using an anti-phosphotyrosine antibody and an antibody specific for the protein substrate. These assays may be practiced in a whole cell or cell-free system. The assays can be used to identify test compds. for use in therapeutic applications to disease processes in which tyrosine kinase or phosphatase activity in a signal transduction pathway contributes to a pathol. process.

IT **446-72-0**, Genistein **70563-58-5**, Herbimycin A
125697-92-9, Lavendustin A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**screening** assays for compds. modulating specific protein tyrosine kinase involved in signal transduction)

RN 446-72-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 70563-58-5 HCAPLUS
CN Geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

—NH_2

RN 125697-92-9 HCAPLUS
CN Benzoic acid, 5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



IT **9025-75-6**, Phosphoprotein phosphatase **80449-02-1**, Protein tyrosine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**screening** assays for compds. modulating specific protein tyrosine kinase involved in signal transduction)
RN 9025-75-6 HCAPLUS
CN Phosphatase, protein phosphoserine/phosphothreonine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 80449-02-1 HCAPLUS
CN Kinase (phosphorylating), protein (tyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:640690 HCAPLUS
DOCUMENT NUMBER: 127:314804
TITLE: Assays for KDR/FLK-1 receptor tyrosine kinase inhibitors, and use of the inhibitors for treatment of vasculogenesis- and angiogenesis-related diseases
INVENTOR(S): **Hirth, Klaus P.**; McMahon, Gerald; Shawver, Laura K.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734920	A1	19970925	WO 1997-US3378	19970304
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9720667	A1	19971010	AU 1997-20667	19970304
PRIORITY APPLN. INFO.:			US 1996-621734	19960321
			WO 1997-US3378	19970304

AB Processes are disclosed for the identification of compds. and pharmaceutical compns. capable of selectively and potently inhibiting KDR/FLK-1 tyrosine kinase signal transduction in order to inhibit vasculogenesis and/or angiogenesis. The invention also relates to compds. and compns. identified using the methods of the invention and the use thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. The invention provides an assay cascade comprised of several "filter steps" of increasing selectivity which identify a limited subset of candidate compds. affecting the VEGF receptor on the mol. level.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)
RN 127464-60-2 HCAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **3359-49-7**, SU 4928 **5812-07-7**, SU 4312 **62540-08-3**, SU 5208 **91822-51-4**, SU 4314 **168835-82-3**, SU 1498 **168835-90-3**, SU 1433 **186611-03-0**, SU 4932 **186611-55-2**, SU 4313 **197592-54-4**, SU 0879 **197592-55-5**, SU 1076 **197592-56-6**, SU 1385 **197592-57-7**, SU 1387 **197592-58-8**, SU 1393 **197592-61-3**, SU 1835 **197592-62-4**, SU 4136 **197592-63-5**, SU 4157 **197592-64-6**, SU 4161

197592-65-7, SU 4209 **197592-66-8**, SU 4304
197592-67-9, SU 4328 **197592-68-0**, SU 4334
197592-69-1, SU 4348 **197592-70-4**, SU 4929
197592-71-5, SU 4936 **197592-72-6**, SU 4943
197592-73-7, SU 4945 **197592-74-8**, SU 5014
197592-75-9, SU 5015 **204005-46-9**, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)

RN 3359-49-7 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 5812-07-7 HCAPLUS
CN 2H-Indol-2-one, 3-[[4-(dimethylamino)phenyl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 62540-08-3 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 91822-51-4 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 168835-82-3 HCAPLUS
CN 2-Propenamide, 2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168835-90-3 HCAPLUS
CN 1,2-Benzenediol, 4-(6,7-dimethyl-2-quinoxalinyl)- (9CI) (CA INDEX NAME)



RN 186611-03-0 HCAPLUS
CN 2H-Indol-2-one, 3-[(2-chloro-4-hydroxyphenyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-55-2 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(1-methylethyl)phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 197592-54-4 HCAPLUS
CN SU 0879 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-55-5 HCAPLUS
CN SU 1076 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-56-6 HCAPLUS
CN SU 1385 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-57-7 HCAPLUS
CN SU 1387 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-58-8 HCAPLUS
CN SU 1393 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-61-3 HCAPLUS
CN SU 1835 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-62-4 HCAPLUS
CN SU 4136 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-63-5 HCAPLUS
CN SU 4157 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-64-6 HCAPLUS
CN SU 4161 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-65-7 HCAPLUS
CN SU 4209 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-66-8 HCAPLUS
CN SU 4304 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-67-9 HCAPLUS
CN SU 4328 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-68-0 HCAPLUS
CN SU 4334 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-69-1 HCAPLUS
CN SU 4348 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-70-4 HCAPLUS
CN SU 4929 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-71-5 HCAPLUS
CN SU 4936 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-72-6 HCAPLUS
CN SU 4943 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-73-7 HCAPLUS
CN SU 4945 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-74-8 HCAPLUS
CN SU 5014 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 197592-75-9 HCAPLUS
CN SU 5015 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 204005-46-9 HCAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



IT **141350-03-0**, Flt-1 VEGF receptor tyrosine kinase
150977-45-0, Flk-1/KDR VEGF receptor tyrosine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)
RN 141350-03-0 HCAPLUS
CN Kinase (phosphorylating), vascular endothelial growth factor receptor, gene flt-1 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 150977-45-0 HCAPLUS
CN Kinase (phosphorylating), gene flk-1 protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **60-18-4**, Tyrosine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phosphorylation; KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)
RN 60-18-4 HCAPLUS
CN L-Tyrosine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:145206 HCAPLUS
DOCUMENT NUMBER: 126:139857
TITLE: **Screening** assays for compounds
INVENTOR(S): Ullrich, Axel; App, Harald; **Hirth, Klaus P.**; Tsai, Jianming
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640276	A1	19961219	WO 1996-US8332	19960603
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9659658	A1	19961230	AU 1996-59658	19960603
EP 873142	A1	19981028	EP 1996-916950	19960603
R: CH, DE, FR, GB, IT, LI				

PRIORITY APPLN. INFO.: US 1995-488156 19950607
WO 1996-US8332 19960603

AB The invention is directed to rapid and quant. assay systems for **screening** test compds., such as **drugs** and ligands, for their ability to modulate tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction. These assays involve monitoring the phosphorylation or dephosphorylation of tyrosine residues on selected substrates involved in signal transduction in a target cell and may be practiced in a whole cell or cell-free system. The assays can be used to identify compds. for use in therapeutic applications to disease processes in which tyrosine kinase or phosphatase activity in a signal transduction pathway contributes to a pathol. process, such as neoplasm, diabetes, anemia, immunodeficiency, inflammation, rheumatoid arthritis, etc.

IT **79747-53-8**, Phosphotyrosine phosphatase **80449-02-1**, Protein tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; **screening** assays for modulators of tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction)

RN 79747-53-8 HCAPLUS
CN Phosphatase, phosphoprotein (phosphotyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 80449-02-1 HCAPLUS
CN Kinase (phosphorylating), protein (tyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **446-72-0**, Genistein **62996-74-1**, Staurosporin
70563-58-5, Herbimycin A **125697-92-9**, Lavendustin A
186371-06-2 186371-07-3 186371-08-4
186371-09-5 186371-10-8 186371-11-9
186371-12-0 186371-13-1 186371-14-2
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(**screening** assays for modulators of tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction)
RN 446-72-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 62996-74-1 HCAPLUS
CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 70563-58-5 HCAPLUS
CN Geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

—NH_2

RN 125697-92-9 HCAPLUS
CN Benzoic acid, 5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 186371-06-2 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-4-(3-methoxypropyl)-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)



RN 186371-07-3 HCAPLUS
CN 1H-1,2,4-Triazole, 3-(1,1-dimethylethyl)-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)



RN 186371-08-4 HCAPLUS
CN 1H-1,2,4-Triazole, 3-[(5-nitro-2-thiazolyl)thio]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 186371-09-5 HCAPLUS
CN 3H-1,2,4-Triazol-3-one, 4-cyclohexyl-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)



RN 186371-10-8 HCAPLUS
CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-4-phenyl- (9CI) (CA INDEX NAME)



RN 186371-11-9 HCAPLUS
CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 186371-12-0 HCAPLUS
CN 1H-1,2,4-Triazole, 3-[(5-nitro-2-thiazolyl)thio]-5-phenyl- (9CI) (CA INDEX NAME)



RN 186371-13-1 HCAPLUS
CN 1H-1,2,4-Triazole, 3-(4-chlorophenyl)-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)



RN 186371-14-2 HCAPLUS
CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **21820-51-9**, Phosphotyrosine
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(**screening** assays for modulators of tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction)
RN 21820-51-9 HCAPLUS
CN L-Tyrosine, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


S
CO2H
NH2
H2O3PO